EU Approves Incyte's Opzelura as First Steroid-Free Topical JAK for Atopic Dermatitis
INCY sits 71% above its 52-week low of $69.695 on elevated volume (3.3× avg).
Summary
The European Commission approved Opzelura cream for moderate atopic dermatitis in adults, making it the first steroid-free topical JAK inhibitor cleared for this indication in the EU. The approval expands Opzelura's European label beyond non-segmental vitiligo and opens a market where up to 7% of adults are affected. It follows a positive CHMP opinion in June and is supported by Phase 3b data showing significant itch relief as early as Day 2 and durable responses through 24 weeks. This comes on the heels of Incyte's strong Q2 report and raised guidance, adding a new growth driver in Europe. The company now has two approved indications for Opzelura in the EU, strengthening its dermatology franchise.
At the time of this announcement, INCY was trading at $119.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26B. The 52-week trading range was $69.70 to $132.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.